Hydromer Announces Strategic Investment by JMEDTECH and Board Restructuring

Hydromer, Inc. has announced a strategic investment in its business by JMEDTECH alongside the formation of a refreshed Board of Directors. Michael Torti will continue to serve as CEO & Director, working with Chairman Jacqueline Zhang and the Board to provide leadership and industry expertise as the company enters its next growth phase. The partnership between Hydromer and JMEDTECH aims to build a future-oriented global medical device coating platform that integrates UV-curable and thermal-cure coating systems supported by advanced coating equipment and regionalized services.

This collaboration represents a significant milestone in expanding technological capabilities and brand influence while establishing JMEDTECH's global expansion strategy. By uniting forces, the companies create a mirror-delivery network covering major medical device markets across Asia and the Americas, significantly enhancing supply chain resilience and customer responsiveness. The platform provides customers worldwide with comprehensive solutions spanning research and development, validation, and mass production capabilities.

Michael Torti expressed enthusiasm about the partnership, stating that combining Hydromer's 40-year innovation history with JMEDTECH's industry leadership will bring the broadest range of coating capabilities to the global medical device marketplace. This includes automatic large-scale coating systems that address evolving market demands. The strategic investment and board restructuring position Hydromer for continued dominance in the surface modification industry while creating enhanced value for shareholders, employees, and customers through expanded global reach and technological integration.